Researcher explores the risk and rewards of stem cell products - Medical Xpress

[Stemcell News]

Researcher explores the risk and rewards of stem cell products Medical Xpress Now, a lawyer from the UCLA School of Law and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA has developed a road map that could help guide researchers, stem cell product manufacturers, ... and more »

More...

[tradeup]

excerpt...

"One of the byproducts of that judicious caution, both of risk of liability and potential risk to patients, Munzer said, has been scientists and biotech companies initially going after the so-called "low hanging fruit" of stem cell treatments, those projects that appear to have the least amount of risk and maximum benefit, such as treatments for retinal disease as opposed to organ regeneration."

Wonder who he may be referring to? ACTC is truly at the tip of the arrow here.